Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, +100.0% YoY · Filed Mar 3, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$33.7 million. As of Sep 30, 2026 it held $768.1 million in cash and investments and $4.9 million in total debt.
Revenue
$0
+100.0% vs year-ago quarter
Net income
$-45.49M
-32.3% vs year-ago quarter
Operating cash flow
$-33.67M
-10.9% vs year-ago quarter
Free cash flow
$-33.70M
-10.9% vs year-ago quarter
EPS
$-0.38
-2.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
128.56M
+17.1% vs year-ago quarter
Net cash
$763.19M
Q3 FY2026
Operating margin
6113.4%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1658551
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 |
| Operating income | -$49.7M | -$45.7M | -$43.8M | -$36.6M | -$36.0M |
| Net income | -$45.5M | -$43.4M | -$41.3M | -$33.0M | -$34.4M |
| Diluted EPS | -$0.38 | -$0.39 | -$0.37 | -$0.30 | -$0.37 |
| Operating cash flow | -$33.7M | -$31.4M | -$36.9M | -$27.9M | -$30.4M |
| Free cash flow | -$33.7M | -$31.4M | — | -$28.0M | -$30.4M |
| Total assets | $786.8M | $264.6M | $293.6M | $332.6M | $362.7M |
| Total liabilities | $33.1M | $25.4M | $20.4M | $27.4M | $30.7M |
| Stockholders' equity | $753.7M | $239.2M | $273.2M | $305.3M | $332.0M |
| Cash and investments | $768.1M | $250.8M | $279.8M | $317.0M | $344.0M |
| Total debt | $4.9M | $5.3M | $5.6M | $6.0M | $5.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
All 440 Amylyx Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.